Kenya's Cervical Cancer Screening Stalls at the Pathologist Shortage
Kenya records more than 5,000 new cervical cancer cases each year, and the screening rate for eligible women has remained below 20 percent for over a decade. The bottleneck is not only a lack of awareness or willingness. It is a severe shortage of pathologists, the specialists who examine tissue samples and confirm whether abnormal cells are precancerous or malignant. Without that confirmation, screening programmes stall at the point of diagnosis.
The Screening Queue That Rarely Moves
Fewer than 200 pathologists serve Kenya's population of roughly 50 million people. Most are concentrated in Nairobi, leaving large regions of the country with no resident pathologist at all. A woman who undergoes a biopsy in Kisumu or Kakamega may wait three months or longer for a result that determines whether she needs treatment. The Kenyan Ministry of Health has acknowledged these delays in national cancer control planning documents.
Screening itself is uneven. Some clinics offer visual inspection with acetic acid, a low-cost method that allows a nurse to see abnormal tissue directly. Others rely on Pap smears, which require laboratory processing. Both pathways eventually depend on pathology for confirmation when results are abnormal. That dependency is where the queue forms.
The consequences are measurable. Women who test positive on initial screening but cannot obtain a confirmatory biopsy result within a reasonable timeframe often disengage from care entirely. The reasons are practical: a referral hospital may be hours away, transport costs a day's wages, and each return visit risks another lost day of work with no guarantee that results will be ready. When the wait is indefinite, the rational choice for many women is to stop coming. This pattern is well recognised in cervical cancer care in Kenya, though the exact proportion who drop out varies by setting and study design.
Why a Pathologist Shortage Stalls Care
Cervical cancer screening works by identifying abnormal cells before they become invasive. HPV testing detects the virus that causes most cases, but a positive HPV result does not mean cancer is present. It means a woman needs further evaluation, usually a colposcopy and possibly a biopsy. The biopsy sample must be processed, stained, and examined under a microscope by a pathologist.
Visual inspection with acetic acid can identify obvious lesions that warrant immediate treatment. But it misses smaller or deeper abnormalities, and it cannot distinguish between low-grade changes that may resolve on their own and high-grade lesions that require removal. A related piece on this site discusses how screening guidelines assume a colonoscopy within reach, a parallel problem where the confirmatory step depends on specialist capacity that may not exist locally.
Biopsy slides from across Kenya are often sent to Nairobi for processing and interpretation. Transport adds days or weeks. Once slides arrive, they join a backlog. A pathologist may review dozens of cases per day, but the volume from a national screening programme quickly exceeds what a small cadre can handle. Results that arrive after cancer has already spread offer little benefit for early intervention.
The Referral-and-Return Problem
Consider the mechanics of a referral. A woman attends a clinic for routine screening. Her visual inspection result is abnormal, and she is told she needs a biopsy. The biopsy is performed that day, but the sample must travel to Nairobi for processing. She is asked to return in six weeks for results.
Six weeks pass. She makes the journey back to the clinic, only to learn the results have not arrived. She is told to come back again. The second trip costs another day of work and another fare. She does not return. This sequence—initial visit, referral, one or more return trips, and eventual attrition—is a common pathway in settings where pathology is centralised and transport is costly. The exact dropout rate is difficult to pin down because loss to follow-up is measured differently across studies, but the direction is consistent: the longer the wait and the more trips required, the fewer women complete the diagnostic process.
The financial burden compounds the logistical one. For a woman earning a modest daily wage, a round trip to a referral hospital can consume a significant portion of her monthly income. When the trip yields no result, the cost of continuing to try rises while the perceived benefit falls. She stops coming.
What Evidence Says Works
The World Health Organization's 2020 strategy calls for 70 percent of women to be screened for cervical cancer by age 35 and again by age 45, using a high-performance test such as HPV DNA testing. HPV testing is more sensitive than visual inspection and can be performed on self-collected samples, which reduces the need for a speculum examination and a trained provider. But a positive HPV test still requires follow-up, and in settings without adequate pathology, that follow-up remains the weak link.
Task-shifting offers a partial solution. Nurses and community health workers can be trained to perform visual inspection and, in some cases, to conduct cryotherapy or thermal ablation immediately when a lesion is visible. This single-visit screen-and-treat approach eliminates the wait for a pathology result. A related piece on this site describes how India trains community health workers for oral cancer screening, a model that has relevance for cervical cancer in similar resource-limited settings.
The trade-off is real. Screen-and-treat with visual inspection alone can overtreat women whose lesions would have resolved without intervention, and it can miss lesions that are not visible. HPV testing followed by immediate treatment of all positive cases is more sensitive but also leads to overtreatment, because most HPV infections clear on their own.
The ideal approach—HPV testing with genotyping and triage—requires laboratory capacity that many Kenyan counties do not have. Genotyping can identify which HPV types are present, allowing clinicians to focus treatment on the highest-risk infections. But it adds cost and complexity, and it still depends on a laboratory to run the test and report the result.
Training More Pathologists Takes Years
Kenya has one pathology training programme, based at the University of Nairobi. It graduates fewer than 20 specialists annually. Expanding that number would require more faculty, more laboratory space, and more funding for residency positions. Even if enrolment doubled tomorrow, the new graduates would not enter the workforce for five to six years.
Retention is another problem. Kenyan pathologists are recruited by laboratories in the United Kingdom, Australia, and the United States, where salaries are substantially higher. Those who remain often work in private facilities in Nairobi, leaving public hospitals and rural counties understaffed. A related piece on this site notes how Indonesia caps specialist referrals for diabetes care at primary clinics, a reminder that specialist shortages are a global pattern with local consequences.
Telepathology offers a partial solution. Digital scanners can capture slide images that are transmitted to a pathologist anywhere with an internet connection. In practice, this requires a slide scanner (often costing tens of thousands of dollars), reliable electricity, and sufficient bandwidth to upload high-resolution images—a constraint in many rural areas. Where these conditions are met, turnaround times can improve because slides no longer need to be physically transported. But telepathology does not solve the underlying shortage of pathologists to read the slides. It only redistributes their time.
Practical Steps for Women and Clinics
Women who are due for screening should ask specifically for an HPV test when it is available, rather than relying solely on visual inspection. HPV testing is more sensitive and can be done on a self-collected sample in some clinics.
Anyone who undergoes a biopsy should request a copy of the pathology report directly, even if the result is normal. Keeping that document makes it easier to seek a second opinion or continue care at a different facility.
Community health workers can be enlisted to follow up with women who have been referred for further evaluation. A phone call or a home visit can be the difference between a woman returning for results and disappearing from the system.
Clinics and county health offices can advocate for local pathology laboratories or for participation in telepathology pilot programmes. Reducing the distance a slide must travel is one of the most direct ways to shorten the wait for a diagnosis.
Finally, supporting organisations that train and retain pathologists in Kenya addresses the root of the problem. Donations to university pathology departments or to professional associations that offer continuing education can help. The effects will take years to appear, but without that investment the queue will not move.
These steps assume that tests, reports, and follow-up systems are within reach. For many women in Kenya, they are not. Advice that places the burden on individuals to navigate a fragmented system can obscure the structural gaps that make such navigation impossible. The most useful actions for women are those paired with clinic- and county-level efforts to expand availability and reduce the number of trips required.
This article is informational and not a substitute for personalised medical advice. Women with concerns about cervical cancer screening or symptoms should consult a qualified healthcare provider.
